Condition: Nasopharyngeal Carcinoma by AJCC V8 Stage · Sponsor: Fourth Affiliated Hospital of Guangxi Medical University
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Nimotuzumab has been granted approval for use in squamous cell carcinoma of head and neck (SCCHN), glioma and nasopharyngeal cancer in different countries. This is a multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of nimotuzumab combined with induction chemotherapy plus chemoradiation and adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.
This description comes directly from the study's public registry record.
Ying Lu, MD · +8607723815405 · 1786734840@qq.com
Always discuss trial participation with your own doctor first.
| People's Hospital of Baise | Baise City, Guangxi, China | Recruiting |
| Affiliated Hospital of Youjiang Medical University for Nationalities | Baise City, Guangxi, China | Recruiting |
| Guilin Medical University, China | Guilin, Guangxi, China | Recruiting |
| Nanxishan Hospital of Guangxi Zhuang Autonomous Region | Guilin, Guangxi, China | Recruiting |
| the Fourth Affiliated Hospital of Guangxi Medical University | Liuzhou, Guangxi, China | Recruiting |
| Second Affiliated Hospital of Guangzhou Medical University | Nanjing, Guangxi, China | Recruiting |
| The First People's Hospital of Qinzhou | Qinzhou, Guangxi, China | Recruiting |
| Wuzhou Red Cross Hospital | Wuzhou, Guangxi, China | Recruiting |
| Liuzhou People's Hospital | Liuzhou, Other (Non U.s.), China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05717790